Paul K. Crane, MD, MPH; Laura E. Gibbons, PhD; Kristen Dams-O鈥機onnor, PhD; et al.
free access
has audio
JAMA Neurol. 2016;73(9):1062-1069. doi:10.1001/jamaneurol.2016.1948
This study uses pooled data from 3 prospective cohort studies to assesse whether traumatic brain injury with loss of consciousness is associated with an increased risk for clinical and neuropathologic findings of Alzheimer disease, Parkinson disease, and other dementias among US adults.
-
Podcast:
Association of TBI and Late-Life Neurodegenerative Conditions (JAMA Neurology)
Liang Wang, MD; Tammie L. Benzinger, MD, PhD; Yi Su, PhD; et al.
free access
JAMA Neurol. 2016;73(9):1070-1077. doi:10.1001/jamaneurol.2016.2078
This study examines the use of [18F]-AV-1451 positron emission tomography imaging in individuals with Alzheimer disease (AD) compared with cognitively normal status in staging AD and determining interactions between 尾-amyloid and tauopathy.
Kamalini G. Ranasinghe, MBBS, PhD; Katherine P. Rankin, PhD; Peter S. Pressman, MD; et al.
free access
JAMA Neurol. 2016;73(9):1078-1088. doi:10.1001/jamaneurol.2016.2016
This case series uses structural MRI to characterize the subtype differences in functional networks of patients with behavioral variant frontotemporal dementia.
Ludwig Kappos, MD; David K. B. Li, MD; Olaf Stüve, MD; et al.
free access
JAMA Neurol. 2016;73(9):1089-1098. doi:10.1001/jamaneurol.2016.1451
This dose-blinded extension phase of the BOLD Study assesses the safety and efficacy of siponimod for up to 24 months in patients with relapsing-remitting multiple sclerosis.
Elena Cortés-Vicente, MD; Eduard Gallardo, PhD; María Ángeles Martínez, BSc; et al.
free access
JAMA Neurol. 2016;73(9):1099-1104. doi:10.1001/jamaneurol.2016.2032
This cross-sectional study examines the clinical features of patients with double-seronegative myasthenia gravis who have cortactin antibodies.
Louise-Laure Mariani, MD; Christelle Tesson, PhD; Perrine Charles, MD, PhD; et al.
free access
has multimedia
JAMA Neurol. 2016;73(9):1105-1114. doi:10.1001/jamaneurol.2016.2215
This case series examines patients with Huntington disease (HD) phenotypes to determine the frequency of HD phenocopies with typical features of HD but without pathological CAG repeat expansions in HTT in an attempt to improve the positive diagnosis rate.
-
Video:
Patient SAL-315-001 With Neurodegeneration With Brain Iron Accumulation
Bastien Joubert, MD; Margaux Saint-Martin, MSc; Nelly Noraz, PhD; et al.
free access
JAMA Neurol. 2016;73(9):1115-1124. doi:10.1001/jamaneurol.2016.1585
This case series describes the clinical and radiographic characteristics of patients with anti鈥揷ontactin-associated protein-like 2 (CASPR2) antibodies in their cerebrospinal fluid.
Gregory S. Day, MD, MSc, FRCPC; Erik S. Musiek, MD, PhD; Catherine M. Roe, PhD; et al.
free access
JAMA Neurol. 2016;73(9):1125-1132. doi:10.1001/jamaneurol.2016.1236
This case-control study uses a family with late-onset autosomal dominant Alzheimer disease caused by a presenilin 1 (PSEN1) gene mutation to mitigate the potential confound of age when comparing autosomal dominant Alzheimer disease and late-onset Alzheimer disease.
Samuel Groeschel, MD; Jörn-Sven Kühl, MD; Annette E. Bley, MD; et al.
free access
JAMA Neurol. 2016;73(9):1133-1140. doi:10.1001/jamaneurol.2016.2067
This case-control study compares the long-term outcome after allogeneic hematopoietic stem cell transplantation compared with nontransplanted patients among a cohort with juvenile metachromatic leukodystrophy.